Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® - TransCon™ CNP NDA submitted in Q1 2025; MAA ...

Ascendis Pharma AS (ASND) reports significant revenue increases for YORVIPATH and SKYTROFA, while navigating higher R&D and SG&A expenses.

Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of SKYTROFA and YORVIPATH for the U.S., European, and other ...

Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launch with long runway to maximize peak sales potential. Management is wisely focusing on applying ...

For example, Yorvipath (palopegteriparatide) is an injectable therapy designed to replace parathyroid hormone in adults with hypoparathyroidism (low parathyroid hormone levels). It is self ...

The analyst’s rating is based on the promising demand for the company’s Yorvipath. A recent survey conducted by endocrinologists revealed a strong uptake for uncontrolled HPT patients since ...

Lead product MBX 2109 is a prodrug of parathyroid hormone (PTH), which is deficient in hypoparathyroidism, and a would rival to Ascendis Pharma's Yorvipath (palopegteriparatide), another PTH ...

The company has already demonstrated the value of its technology in two approved products, namely Yorvipath (palopegteriparatide), a modified version of parathyroid hormone (PTH), which is for the ...

YORVIPATH addresses chronic hypoparathyroidism, a condition characterised by low or absent levels of PTH. It received approval in the European Union in November 2023 for adults with this condition ...